Fintel reports that on May 10, 2023, Baird kept protection of Exact Sciences (NASDAQ: EXAS) with a Outperform suggestion. Expert Price Forecast Suggests 9.61% Upside As of April 24, 2023, the typical 1 year cost target for Exact Sciences is 77.82. The projections vary from a low of 55.55 to a high of $99.75. The typical rate target represents a boost of 9.61% from its most current reported closing rate of 71.00. See our leaderboard of business with the biggest cost target upside. The forecasted yearly earnings for Exact Sciences is 2,322 MM, a boost of 5.54%. The forecasted yearly non-GAAP EPS is -2.69. What is the Fund Sentiment? There are 1080 funds or organizations reporting positions in Exact Sciences. This is a boost of 108 owner(s) or 11.11% in the last quarter. Typical portfolio weight of all funds devoted to EXAS is 0.25%, a boost of 37.63%. Overall shares owned by organizations reduced in the last 3 months by 3.57% to 198,198 K shares. The put/call ratio of EXAS is 0.79, showing a bullish outlook. What are Other Shareholders Doing? ARK Investment Management holds 11,379 K shares representing 6.33% ownership of the business. In it’s previous filing, the company reported owning 16,040 K shares, representing a reduction of 40.96%. The company reduced its portfolio allowance in EXAS by 22.94% over the last quarter. Wellington Management Group Llp holds 10,252 K shares representing 5.70% ownership of the business. In it’s previous filing, the company reported owning 11,228 K shares, representing a decline of 9.52%. The company increased its portfolio allowance in EXAS by 30.99% over the last quarter. ARKK – ARK Innovation ETF holds 8,818 K shares representing 4.90% ownership of the business. In it’s previous filing, the company reported owning 11,226 K shares, representing a decline of 27.31%. The company increased its portfolio allotment in EXAS by 52.69% over the last quarter. Jpmorgan Chase holds 7,750 K shares representing 4.31% ownership of the business. In it’s previous filing, the company reported owning 4,634 K shares, representing a boost of 40.20%. The company increased its portfolio allotment in EXAS by 133.93% over the last quarter. VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 5,409 K shares representing 3.01% ownership of the business. In it’s previous filing, the company reported owning 5,271 K shares, representing a boost of 2.56%. The company increased its portfolio allotment in EXAS by 44.43% over the last quarter. Specific Sciences Background Information (This description is supplied by the business.) A leading service provider of cancer screening and diagnostic tests, Exact Sciences non-stop pursues smarter options offering the clearness to take life-altering action, earlier. Structure on the success of Cologuard and Oncotype DX, Exact Sciences is purchasing its item pipeline to handle a few of the most dangerous cancers and enhance client care. Precise Sciences joins visionary partners to assist advance the battle versus cancer. See all Exact Sciences regulative filings. This story initially appeared on Fintel. The views and viewpoints revealed herein are the views and viewpoints of the author and do not always show those of Nasdaq, Inc.
Baird Maintains Exact Sciences (EXAS) Outperform Recommendation
